HOPKINTON, Mass., Aug. 22, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced it will present at the 18th Annual Rodman & Renshaw Global Investment Conference on Tuesday, September 13th at 11:40 am ET. Martin Driscoll, President and CEO of Spring Bank Pharmaceuticals, will provide an overview of the Company's business during the live presentation and Jon Freve, CFO, will also be in attendance.
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website and can request a one-on-one meeting with the Company.
Live audio webcasts of the presentations will be available on the company’s website at http://ir.springbankpharm.com or visit www.rodmanevents.com. The webcast replay will remain available for 90 days following the live presentation.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus.
Jon Freve Chief Financial Officer (508) 473-5993 email@example.com
Source:Spring Bank Pharmaceuticals Inc.